Iovance Biotherapeutics Revenue and Competitors

Location

$1.2B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Iovance Biotherapeutics's estimated annual revenue is currently $13.8M per year.(i)
  • Iovance Biotherapeutics received $172.5M in venture funding in January 2018.
  • Iovance Biotherapeutics's estimated revenue per employee is $25,082
  • Iovance Biotherapeutics's total funding is $1.2B.

Employee Data

  • Iovance Biotherapeutics has 550 Employees.(i)
  • Iovance Biotherapeutics grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

keywords:N/A

$1.2B

Total Funding

550

Number of Employees

$13.8M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Iovance Biotherapeutics News

2022-04-19 - Iovance: Onward To Approval

Iovance Biotherapeutics' potency assay for lifileucel caused a huge haircut in the share price. As Iovance has now resolved the assay debacle,...

2022-04-06 - Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for...

2022-03-22 - Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Iovance Biotherapeutics (NASDAQ:IOVA) is a startup biopharmaceutical company located in San Carlos, California. The company is in the...

2021-11-12 - Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting

21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET SAN CARLOS, Calif., and WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$226.7M5534%N/A
#2
$7.5M65932%N/A
#3
$292.1M9198%N/A
#4
$634.3M16721%$144.1M
#5
$397.5M1958N/AN/A

Iovance Biotherapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-21$57.5MUndisclosedJefferies LLCArticle
2018-01-26$143.8MUndisclosedJefferies LLCArticle
2018-01-31$172.5MUndisclosedJefferies LLCArticle